DE347588T1 - Heparinderivate und verfahren zu deren herstellung. - Google Patents
Heparinderivate und verfahren zu deren herstellung.Info
- Publication number
- DE347588T1 DE347588T1 DE198989109030T DE89109030T DE347588T1 DE 347588 T1 DE347588 T1 DE 347588T1 DE 198989109030 T DE198989109030 T DE 198989109030T DE 89109030 T DE89109030 T DE 89109030T DE 347588 T1 DE347588 T1 DE 347588T1
- Authority
- DE
- Germany
- Prior art keywords
- process according
- sodium
- potassium
- aqueous solution
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 title claims 6
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000002628 heparin derivative Substances 0.000 claims abstract 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims abstract 3
- 239000003638 chemical reducing agent Substances 0.000 claims abstract 3
- 238000001228 spectrum Methods 0.000 claims abstract 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000011591 potassium Substances 0.000 claims 3
- 229910052700 potassium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical class [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical class [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 230000001371 heparinic effect Effects 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 235000011147 magnesium chloride Nutrition 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 235000011151 potassium sulphates Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 abstract 3
- 229920000669 heparin Polymers 0.000 abstract 3
- 230000002785 anti-thrombosis Effects 0.000 abstract 2
- 230000002008 hemorrhagic effect Effects 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- -1 alkali metal salts Chemical class 0.000 abstract 1
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000014508 negative regulation of coagulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
Claims (7)
1. Neue Heparinderivate, gekennzeichnet durch Signale im C-NMR-Spektrum bei etwa 53 und etwa 54
ppm, eine spezifische Drehkraft zwischen etwa +50° und etwa +90° in wäßriger Lösung, einen Schwefelgehalt zwischen etwa
8% und etwa 11% und ein SuIfat/Carboxyl-Verhältnis zwischen
etwa 1,5 0 und etwa 2,20.
2. Verfahren zur Herstellung von neuen Heparinderivaten, die durch Signale im C-NMR-Spektrum bei etwa 53 und etwa
54 ppm, eine spezifische Drehkraft zwischen etwa +50° und etwa +90° in wäßriger Lösung, einen Schwefelgehalt zwischen
etwa 8% und etwa 11% und ein SuIfat/Carboxy1-Verhältnis
zwischen etwa 1,50 und etwa 2,20 charakterisiert sind, dadurch gekennzeichnet , daß man eine wäßrige
Lösung eines heparinischen Materials mit einer Base eines Alkali- oder Erdalkalimetalls bei einer Konzentration
zwischen etwa 0,01n und etwa In in Gegenwart einer Konzentration zwischen 0 und etwa In eines Salzes eines Alkalioder
Erdalkalimetalls, fakultativ in Gegenwart einer katalytischen Menge eines Reduktionsmittels, über einen Zeitraum
zwischen 0,5 und 24 Stunden bei einer Temperatur zwischen etwa 35°C-und etwa 700C behandelt, daß man gegebenenfalls
das Reaktionsgemisch durch Perkolation durch ein Ionenaustauscher-Harz oder durch Dialyse reinigt und daß man die
Verbindungen, die eine so modifizierte Struktur haben, durch Zugabe von etwa 2 bis etwa 4 Volumina eines Alkohols
mit 1 bis 3 Kohlenstoffatomen bei einem pH-Wert von etwa neutral ausfällt.
3. Verfahren nach Anspruch 2, dadurch gekennzeichnet , daß man die Base aus Natrium-, Kalium-,
und Bariumhydroxiden auswählt.
4. Verfahren nach Anspruch 2, dadurch gekennzeichnet , daß man die Salze aus Natrium-, Kalium-,
Barium-, Calcium- und Magnesiumchloriden und -acetaten und den Natrium-, Kalium- und Magnesiumsulfaten auswählt.
5. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß das Reduktionsmittel Natriumborhydrid
ist.
6. Verfahren nach Anspruch 2, dadurch gekennzeichnet , daß man die Verbindungen durch Zugabe
von etwa 2,5 Volumina Ethylalkohol ausfällt.
7. Verwendung der Verbindungen nach Anspruch 1 zur Herstellung von pharmazeutischen Präparaten zur Behandlung
von thrombotischen pathologischen Zuständen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8803504A IT1234508B (it) | 1988-06-10 | 1988-06-10 | Derivati eparinici e procedimento per la loro preparazione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE347588T1 true DE347588T1 (de) | 1990-05-23 |
Family
ID=11108618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE68917040T Expired - Fee Related DE68917040T2 (de) | 1988-06-10 | 1989-05-19 | Heparinderivate und Verfahren zu deren Herstellung. |
| DE198989109030T Pending DE347588T1 (de) | 1988-06-10 | 1989-05-19 | Heparinderivate und verfahren zu deren herstellung. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE68917040T Expired - Fee Related DE68917040T2 (de) | 1988-06-10 | 1989-05-19 | Heparinderivate und Verfahren zu deren Herstellung. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5010063A (de) |
| EP (1) | EP0347588B1 (de) |
| JP (1) | JPH0739442B2 (de) |
| KR (1) | KR960015110B1 (de) |
| AT (1) | ATE109164T1 (de) |
| CA (1) | CA1309402C (de) |
| DE (2) | DE68917040T2 (de) |
| DK (1) | DK173818B1 (de) |
| ES (1) | ES2012748T3 (de) |
| FI (1) | FI94534C (de) |
| GR (1) | GR900300018T1 (de) |
| IE (1) | IE64830B1 (de) |
| IL (1) | IL90411A (de) |
| IT (1) | IT1234508B (de) |
| NO (1) | NO174259C (de) |
| NZ (1) | NZ229212A (de) |
| PT (1) | PT90817B (de) |
| ZA (1) | ZA893882B (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1234508B (it) * | 1988-06-10 | 1992-05-19 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
| IT1234826B (it) * | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
| US5232040A (en) * | 1990-07-12 | 1993-08-03 | Lanxide Technology Company, Lp | Method for reducing metal content of self-supporting composite bodies and articles formed thereby |
| IT1243987B (it) * | 1990-10-29 | 1994-06-28 | Derivati Organici Lab | Procedimento per la preparazione di epossi-eparidi prodotti ottenuti ecomposizioni farmaceutiche che li contengono |
| IT1254216B (it) * | 1992-02-25 | 1995-09-14 | Opocrin Spa | Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
| IT1260137B (it) * | 1992-04-17 | 1996-03-28 | Alfa Wassermann Spa | Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato |
| IT1260136B (it) * | 1992-04-17 | 1996-03-28 | Alfa Wassermann Spa | Glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonicosostituito con radicali nucleofili in posizione 3 |
| US6750207B1 (en) | 1992-05-01 | 2004-06-15 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
| US5861382A (en) * | 1992-05-01 | 1999-01-19 | Yeda Research And Development Co. Ltd. | Methods for regulation of active TNF-α |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| US5296471A (en) * | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
| IT1264102B1 (it) * | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali |
| IT1264101B1 (it) * | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 |
| US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
| US5763427A (en) * | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US5744457A (en) * | 1995-03-31 | 1998-04-28 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US6001820A (en) * | 1995-03-31 | 1999-12-14 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| CA2235223A1 (en) | 1995-10-30 | 1997-05-09 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from heparinase i |
| US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| KR100512671B1 (ko) * | 1996-11-27 | 2005-09-07 | 아벤티스 파마슈티칼스 인크. | 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물 |
| US6106454A (en) * | 1997-06-17 | 2000-08-22 | Medtronic, Inc. | Medical device for delivering localized radiation |
| US6203536B1 (en) * | 1997-06-17 | 2001-03-20 | Medtronic, Inc. | Medical device for delivering a therapeutic substance and method therefor |
| US6013099A (en) | 1998-04-29 | 2000-01-11 | Medtronic, Inc. | Medical device for delivering a water-insoluble therapeutic salt or substance |
| JP2003527822A (ja) * | 1998-08-27 | 2003-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ |
| US7056504B1 (en) | 1998-08-27 | 2006-06-06 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II |
| CA2370539C (en) | 1999-04-23 | 2009-01-06 | Massachusetts Institute Of Technology | System and method for notating polymers |
| HUP0201712A3 (en) * | 1999-06-30 | 2003-03-28 | Weitz Jeffrey I Ancaster | Clot associated coagulation factors inhibiting heparin compositions |
| CA2402160C (en) | 2000-03-08 | 2012-02-14 | Massachusetts Institute Of Technology | Heparinase iii and uses thereof |
| US7259152B2 (en) | 2000-06-07 | 2007-08-21 | Alfa Wasserman, Inc. | Methods and compositions using sulodexide for the treatment of diabetic nephropathy |
| JP2004507562A (ja) * | 2000-09-08 | 2004-03-11 | ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド | 抗血栓性組成物 |
| JP4911865B2 (ja) | 2000-09-12 | 2012-04-04 | マサチューセッツ インスティテュート オブ テクノロジー | 低分子量ヘパリンに関連する方法および生成物 |
| JP2004523479A (ja) * | 2000-10-18 | 2004-08-05 | マサチューセッツ インスティテュート オブ テクノロジー | 多糖の肺送達に関する方法および産物 |
| US7285536B2 (en) * | 2001-12-05 | 2007-10-23 | Yeda Research And Development Co., Ltd. | Anti-cancer therapeutic compounds |
| EP2284535A1 (de) | 2002-03-11 | 2011-02-16 | Momenta Pharmaceuticals, Inc. | Heparine mit niedrigem Molekulargewicht |
| ITMI20031679A1 (it) * | 2003-08-29 | 2005-02-28 | Opocrin Spa | Processo per la produzione di eparine a basso peso |
| EP1582531A1 (de) | 2004-03-24 | 2005-10-05 | Aventis Pharma S.A. | Verfahren zur Oxydierung nicht-fraktionierten Heparins und die Detektion der Anwesenheit oder Abwesenheit von Glykoserin in Heparin und in von Heparin abgeleiteten Produkten |
| US7608246B2 (en) * | 2005-09-02 | 2009-10-27 | The Brigham And Women's Hospital, Inc. | Apolipoprotein E as an adjuvant for lipid antigens |
| ATE552004T1 (de) | 2005-11-30 | 2012-04-15 | Istituto G Ronzoni | Oral verabreichbare heparinderivate |
| US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
| US8435795B2 (en) * | 2010-01-19 | 2013-05-07 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| CN103209997B (zh) * | 2010-09-14 | 2016-03-16 | 国立大学法人宫崎大学 | 高纯度肝素及其制备方法 |
| WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| RU2639574C2 (ru) * | 2016-05-23 | 2017-12-21 | Алексей Георгиевич Александров | Способ получения низкомолекулярного гепарина |
| BR112022000255A8 (pt) | 2019-07-09 | 2022-03-22 | Optimvia Llc | Métodos para sintetizar polissacarídeos anticoagulantes |
| EP4182452A4 (de) | 2020-07-14 | 2024-07-31 | Optimvia Llc | Verfahren zur synthese von nicht-antikoagulierendem heparansulfat |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB863235A (en) * | 1958-07-05 | 1961-03-22 | Roussel Uclaf | Improvements in or relating to organic compounds related to heparin |
| US3016331A (en) * | 1960-01-28 | 1962-01-09 | Ormonoterapia Richter Spa | Purification of heparin |
| IT1083903B (it) * | 1977-08-09 | 1985-05-25 | Lobo Srl | Oligo-eteropolisaccaridi con attivita' eparinosimili,procedimento per il loro ottenimento e relative composizioni terapeutiche |
| IT1195497B (it) * | 1983-03-08 | 1988-10-19 | Opocrin Spa | Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina |
| DE3422518A1 (de) * | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen |
| ES2003197A6 (es) * | 1987-01-05 | 1988-10-16 | Rovi Lab Farmaceut Sa | Procedimiento de despolimerizacion de la heparina para la obtencion de una heparina de bajo peso molecular dotada de actividad antitrombotica |
| IT1234508B (it) * | 1988-06-10 | 1992-05-19 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
-
1988
- 1988-06-10 IT IT8803504A patent/IT1234508B/it active
-
1989
- 1989-05-19 DE DE68917040T patent/DE68917040T2/de not_active Expired - Fee Related
- 1989-05-19 ES ES89109030T patent/ES2012748T3/es not_active Expired - Lifetime
- 1989-05-19 DE DE198989109030T patent/DE347588T1/de active Pending
- 1989-05-19 AT AT89109030T patent/ATE109164T1/de not_active IP Right Cessation
- 1989-05-19 EP EP89109030A patent/EP0347588B1/de not_active Expired - Lifetime
- 1989-05-22 NZ NZ229212A patent/NZ229212A/xx unknown
- 1989-05-23 ZA ZA893882A patent/ZA893882B/xx unknown
- 1989-05-26 US US07/357,548 patent/US5010063A/en not_active Expired - Lifetime
- 1989-05-26 IL IL90411A patent/IL90411A/xx not_active IP Right Cessation
- 1989-06-09 JP JP1148211A patent/JPH0739442B2/ja not_active Expired - Fee Related
- 1989-06-09 NO NO892366A patent/NO174259C/no not_active IP Right Cessation
- 1989-06-09 PT PT90817A patent/PT90817B/pt not_active IP Right Cessation
- 1989-06-09 CA CA000602338A patent/CA1309402C/en not_active Expired - Fee Related
- 1989-06-09 DK DK198902850A patent/DK173818B1/da not_active IP Right Cessation
- 1989-06-09 KR KR1019890007930A patent/KR960015110B1/ko not_active IP Right Cessation
- 1989-06-09 FI FI892850A patent/FI94534C/fi active IP Right Grant
- 1989-06-12 IE IE176289A patent/IE64830B1/xx not_active IP Right Cessation
-
1991
- 1991-06-07 GR GR90300018T patent/GR900300018T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE347588T1 (de) | Heparinderivate und verfahren zu deren herstellung. | |
| DE69012154T2 (de) | Heparinderivate und Verfahren zu ihrer Herstellung. | |
| DE3102621C2 (de) | ||
| DE121067T1 (de) | Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin. | |
| DE60034601T2 (de) | Verfahren zur herstellung von polyphenolischen adhäsionsproteinen | |
| US4788281A (en) | Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof | |
| DE2421655A1 (de) | Thermoplastische werkstoffe ohne thrombose erzeugende wirkung | |
| DE268885T1 (de) | Verfahren zur kontrollierten depolymerisierung von polysacchariden. | |
| DE3771362D1 (de) | Verfahren zur herstellung von sehr reinem dermatansulfat und pharmazeutische zusammensetzungen, welche dieses enthalten. | |
| ATE11784T1 (de) | Verfahren zur herstellung von eisen (iii)hydroxid-dextran-komplexen und diese enthaltende pharmazeutische sterile loesung. | |
| CH616637A5 (de) | ||
| KR0184260B1 (ko) | 항트롬보 활성을 지닌 황산화 글리코스아미노글리큐로난 | |
| DE602004012314T2 (de) | Niedermolekulare polysaccharide mit antithrombotischer wirkung | |
| EP0537429B1 (de) | Modifizierte Huminate, Verfahren zu ihrer Herstellung und Verwendung | |
| DE2616761C3 (de) | Verfahren zur Gewinnung von Urokinase | |
| DE2321196A1 (de) | Entfernung von quecksilber aus abwasser | |
| DE68914861T2 (de) | Verfahren zur Herstellung eines Copolymers aus zwei alpha-Aminsäuren. | |
| DE2714252C2 (de) | Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten | |
| DE4119029C2 (de) | ||
| EP0120182B1 (de) | Verfahren zur Gewinnung von D,L-Homocystin | |
| JPH11130801A (ja) | 低分子ヘパリンの製造法 | |
| DE2924566A1 (de) | Komplex des dreiwertigen eisens mit chondroitinschwefelsaeure, verfahren zu dessen herstellung und pharmazeutische zusammensetzung | |
| DE1617930C (de) | Verfahren zur Reinigung roher Präparate des Proteasen-Inhibitors aus Rinderlunge | |
| DE1767404A1 (de) | Verfahren zur Gewinnung von Lysozym | |
| AT231614B (de) | Verfahren zur Herstellung von künstlichen Mineralwässern bzw. künstlich verstärkten Mineralwässern |